Corvus Pharmaceuticals CRVS Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's foreign currency translation gains (losses)?
- Corvus Pharmaceuticals (CRVS) reported foreign currency translation gains (losses) of $104K in Q1 2026.
- How has Corvus Pharmaceuticals's foreign currency translation gains (losses) changed year-over-year?
- Corvus Pharmaceuticals's foreign currency translation gains (losses) increased by 82.5% year-over-year, from $57K to $104K.
- What is the long-term trend for Corvus Pharmaceuticals's foreign currency translation gains (losses)?
- Over 2 years (2021 to 2025), Corvus Pharmaceuticals's foreign currency translation gains (losses) has grown at a -53.3% compound annual growth rate (CAGR), from $1.87M to $409K.
- What does foreign currency translation gains (losses) mean?
- This represents the gains or losses arising from the translation of financial statements of foreign subsidiaries from their functional currency into the reporting currency. It accounts for the impact of exchange rate fluctuations on the value of international assets and liabilities. This metric is essential for assessing the sensitivity of the company's global financial position to currency market volatility.